CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharmaceuticals' Third Quarter 2012 Financial Results Conference Call
Tuesday, November 6, 2012 at 11:30 a.m. ET / 8:30 a.m. PT
Live on the Internet. Simply log onto our Web site listed above.
D. Wade Walke, Ph.D.
Executive Director, Corporate Communications and Investor Relations
Amy Blackley, Ph.D.
Associate Director, Corporate Communications
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, in the United States and Europe following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE Isis Pharmaceuticals, Inc.